2022
Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2021
Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)
Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.Peer-Reviewed Original ResearchTesticular nonseminomatous germ cell tumorsNonseminomatous germ cell tumorsGerm cell tumorsAccurate stagingCell tumorsStage ITumorsStaging
2020
Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).
Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.Peer-Reviewed Original ResearchNonseminomatous germ cell tumorsRetroperitoneal lymph node dissectionLymph node countOverall survivalLN countStage IPrimary retroperitoneal lymph node dissectionTesticular nonseminomatous germ cell tumorsMultivariate analysisClinical stage ILymph node dissectionNational Cancer DatabaseSingle-center studyKaplan-Meier methodGerm cell tumorsNode countPT2 diseaseNode dissectionAnalytic cohortFavorable survivalCenter studyCell tumorsCancer DatabaseTherapeutic implicationsAcademic centersAccuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancer